Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 6:eabf4063. doi: 10.1126/science.abf4063

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1 — (A) Cross-sectional Spike IgG from COVID-19 subject plasma samples (n=228). Continuous decay preferred model for best fit curve, t_1/2 = 140 days, 95% CI: 89-325 days. R = -0.23, p=0.0006. (B) Longitudinal Spike IgG (n=51), average t_1/2 = 103 days, 95% CI: 65-235 days (C) Cross-sectional RBD IgG. Continuous decay preferred model for best fit curve, t_1/2 = 83 days, 95% CI: 62 to 126 days. R = -0.36, p<0.0001. (D) Longitudinal RBD IgG, average t_1/2 = 69 days, 95% CI: 58-87 days (E) Cross-sectional SARS-CoV-2 PSV neutralizing titers. One-phase decay (blue line) preferred model for best fit curve, initial t_1/2 = 27 days, 95% CI 11-157d. R = -0.32. Continuous decay fit line shown as black line. (F) Longitudinal PSV neutralizing titers of SARS-CoV-2 infected subjects, average t_1/2 = 90 days, 95% CI: 70-125 days. (G) Cross-sectional Nucleocapsid IgG. Continuous decay preferred model for best fit curve, t_1/2 = 68 days, 95% CI: 50-106 days. R = -0.34, p<0.0001. (H) Longitudinal Nucleocapsid IgG, average t_1/2 = 68 days, 95% CI: 55-90 days. (I) Cross-sectional Spike IgA titers. One-phase decay (blue line) preferred model for best fit curve, initial t_1/2 = 11 days, 95% CI 5-25d. R = -0.30. Continuous decay fit shown as black line. (J) Longitudinal Spike IgA, t_1/2 = 210 days, 95% CI 126-627 days. (K) Cross-sectional RBD IgA. One-phase decay (blue line) preferred model for best fit curve, initial t_1/2 = 27 days, 95% CI: 15-59 days. R = -0.45. Continuous decay line fit shown in black. (L) Longitudinal RBD IgA, average t_1/2 = 74 days, 95% CI: 56-107 days. For cross-sectional analyses, SARS-CoV-2 infected subjects (white circles, n=238) and unexposed subjects (gray circles, n=51). For longitudinal samples, SARS-CoV-2 subjects (n=51). The dotted black line indicates limit of detection (LOD). The dotted green line indicates limit of sensitivity (LOS) above uninfected controls. Unexposed = gray, COVID subjects = white. Log data analyzed in all cases. Thick blue line represents best fit curve. When two fit curves are shown, the thin black line represents the alternative fit curve.